Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
06 janv. 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 6, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results...
Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
17 déc. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Dec 17, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
24 nov. 2014 16h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 24, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
18 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 18, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent...
Arch Therapeutics Will Present at Two Investor Conferences in November
10 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
06 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 6, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device ™, announced that an independent...
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
23 oct. 2014 08h15 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Oct 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced today that it is...
Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
30 sept. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 30, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced that it will be featured as a...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
23 sept. 2014 08h50 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 23, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
16 sept. 2014 11h20 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Sep 16, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding...